Results 1 to 10 of about 29,467 (290)

Reversion of anergy signatures in clonal CD21low B cells of mixed cryoglobulinemia after clearance of HCV viremia. [PDF]

, 2017
Hepatitis C virus (HCV) causes mixed cryoglobulinemia (MC) by driving clonal expansion of IgM+CD27+ B cells. These cells display both the features of anergy induced by continual engagement of the B cell receptor (BCR), such as high expression of ...
Casato, Milvia, Colantuono, Stefania, DEL PADRE, Martina, Fiorilli, Massimo, Marrapodi, Ramona, Mitrevski, Milica, Todi, Laura, Visentini, Marcella   +7 more
core   +1 more source

Retreatment Options Following HCV Direct-Acting Antiviral Failure [PDF]

Current Treatment Options in Infectious Diseases, 2017
Despite the excellent efficacy of direct acting antivirals (DAA) for hepatitis C virus (HCV), treatment failures do occur. Until recently, retreatment decisions after DAA failure were influenced by the number of available agents, concerns about HCV drug resistance, and lack of data regarding retreatment.
Autumn, Zuckerman, Cody A, Chastain, Susanna, Naggie   +2 more
openaire   +2 more sources

Hepatitis C virus cell-cell transmission and resistance to direct-acting antiviral agents [PDF]

, 2014
Hepatitis C virus (HCV) is transmitted between hepatocytes via classical cell entry but also uses direct cell-cell transfer to infect neighboring hepatocytes.
A Owsianka, A Sigal, Aleem Siddiqui, Arvind H. Patel, AS Lok, AW Tarr, B Bartolini, B Sainz Jr, C Hezode, C Lee, C Nathan, C Sarrazin, CL Brimacombe, CM Lange, CT Jones, D Masson, D Trono, EJ Gane, Eric Soulier, F Kuonen, F Poordad, F Poordad, Fei Xiao, François Habersetzer, G Koutsoudakis, H Kwon, H Yan, H Zhu, Heidi Barth, I Fofana, I Fofana, I Fofana, IA Abela, IM Jacobson, Isabel Fofana, J Grove, J Lupberger, J Witteveldt, J Zhong, Jens Bukh, JG McHutchison, JM Gottwein, JM Gottwein, JM Pawlotsky, JM Pawlotsky, JM Pawlotsky, JM Timpe, L Rong, L Zona, Laura Heydmann, LW Meredith, MB Zeisel, MB Zeisel, Michel Doffoël, Mirjam B. Zeisel, MN Zahid, MS Sulkowski, MT Catanese, N Shi, O Lenz, P Zhong, PM Trembling, Q Sattentau, S Haid, T Pietschmann, T Pietschmann, T Wakita, Thomas F. Baumert, TJ Liang, TK Scheel, V Soriano, VD Cataldo, ZY Keck   +72 more
core   +7 more sources

Direct-Acting Antiviral Therapy Outcomes in Canadian Chronic Hepatitis C Telemedicine Patients

Annals of Hepatology, 2017
Introduction: Many of the 300,000 HCV-infected Canadians live in under-served and remote areas without access to HCV healthcare specialists. Telemedicine (TM) and advances in HCV management can facilitate linkage of these marginalized patients to ...
Curtis L. Cooper, Holly Hatashita, Daniel J. Corsi, Parmvir Parmar, Raymond Corrin, Gary Garber   +5 more
doaj   +1 more source

Polyclonal and monoclonal B lymphocytes response in HCV-infected patients treated with direct-acting antiviral agents [PDF]

, 2017
Hepatitis C virus (HCV) chronic infection can be associated with extrahepatic manifestations such as mixed cryoglobulinaemia and lymphoproliferative disorders that are endowed with increased rates of morbidity and all-cause mortality.
Burra, Patrizia, Farinati, Fabio, Floreani, Annarosa, Fogar, Paola, Franceschet, Enrica, Gambato, Martina, Nabergoj, Mitja, Pantano, G, Piva, Elisa, Plebani, Mario, Russo, FRANCESCO PAOLO, Schiavinato, Alvise, Tosato, Francesca, Zanetto, Alberto   +13 more
core   +1 more source

‘It’s been a long haul, a big haul, but we’ve made it’: hepatitis C virus treatment in post-transplant patients with virus recurrence: An interpretative phenomenological analysis [PDF]

, 2018
The lived experience of both interferon-based and new interferon-free treatments in patients with hepatitis C virus remains understudied. To explore their journey through hepatitis C virus treatment, we interviewed seven post-transplant patients with ...
Chouliara, Zoe, Dickson, Adele, Flowers, Paul, Hayes, Peter, Krzeczkowska, Anna   +4 more
core   +3 more sources

Direct Acting Antivirals for the Treatment of Chronic Viral Hepatitis

Scientifica, 2012
The development and evaluation of antiviral agents through carefully designed clinical trials over the last 25 years have heralded a new dawn in the treatment of patients chronically infected with the hepatitis B and C viruses, but not so for the D virus
Peter Karayiannis
doaj   +1 more source

Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapy [PDF]

Clinical and Molecular Hepatology, 2020
The treatment of chronic hepatitis C (CHC) has been revolutionized in an era of all-oral direct-acting antivirals (DAAs) since 2014. Satisfactory treatment efficacy and tolerability can be provided by novel DAAs.
Chung-Feng Huang, Ming-Lung Yu
doaj   +1 more source

HIV/HCV Antiviral Drug Interactions in the Era of Direct-acting Antivirals [PDF]

Journal of Clinical and Translational Hepatology, 2016
Therapy for human immunodeficiency virus (HIV) and chronic hepatitis C has evolved over the past decade, resulting in better control of infection and clinical outcomes; however, drug-drug interactions remain a significant hazard. Joint recommendations from the American Association for the Study of Liver Diseases and the Infectious Diseases Society of ...
Rice, Donald P., Faragon, John J., Banks, Sarah, Chirch, Lisa M.   +3 more
openaire   +2 more sources

Race affects SVR12 in a large and ethnically diverse hepatitis C-infected patient population following treatment with direct-acting antivirals: Analysis of a single-center Department of Veterans Affairs cohort. [PDF]

, 2018
Hepatitis C virus (HCV) infection is a major cause of chronic liver disease. HCV cure has been linked to improved patient outcomes. In the era of direct-acting antivirals (DAAs), HCV cure has become the goal, as defined by sustained virological response ...
Benhammou, Jihane N, Bhattacharya, Debika, Dixit, Ram, Dixit, Vivek, Dong, Tien S, Han, Steven B, Jackson, Samuel, Kawamoto, Jenna, May, Folasade P, Pisegna, Joseph R   +9 more
core   +1 more source